tranilast
Sign in to saveAlso known as MK-341, SB-252218, MK 341, N-(3,4-Dimethoxycinnamoyl)anthranilic acid, tranilastum
Tranilast (INN, brand name Rizaben) is an antiallergic drug. It was developed by Kissei Pharmaceuticals and was approved in 1982 for use in Japan and South Korea for bronchial asthma. Indications for keloid and hypertrophic scar were added in the 1980s.
Research
840 papers- Anti-cancer effects of Tranilast: An update.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021
- Tranilast: a review of its therapeutic applications.Pharmacological research · 2015
- Tranilast: a potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19.Immunopharmacology and immunotoxicology · 2021
- Effect of Tranilast on the Frequency of Invasive Treatment for Extra-Abdominal Desmoid Fibromatosis.Journal of Nippon Medical School = Nippon Ika Daigaku zasshi · 2023
- Unlocking the potential of tranilast: Targeting fibrotic signaling pathways for therapeutic benefit.International immunopharmacology · 2024
via PubMed
Wikidata facts
- Mass
- 327.111
- Has use
- medication
Show 4 more facts
- chemical formula
- C₁₈H₁₇NO₅
- canonical SMILES
- COC1=C(C=C(C=C1)C=CC(=O)NC2=CC=CC=C2C(=O)O)OC
- isomeric SMILES
- COC1=C(C=C(C=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O)OC
- World Health Organisation international non-proprietary name
- tranilast
Sources (3)
via Wikidata · CC0
~4 min read
Encyclopedic overview
9 sectionsContents
- Medical uses
- Interactions
- Adverse effects
- Society and culture
- Pharmacology
- Chemistry
- Research
- History
- References
{{Infobox drug | IUPAC_name = 2-{[(2E)-3-(3,4-Dimethoxyphenyl)prop-2-enoyl]amino}benzoic acid | image = Tranilast.svg | image_class = skin-invert-image
| tradename = | Drugs.com = | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = Not FDA approved | legal_status = Rx-only | routes_of_administration = Oral
Excerpted from Wikipedia’s “tranilast” article, available under the CC BY-SA 4.0 licence.